1. Scrip
  3. >>Clinical Trials

Anti-Aging Firm Unity Stumbles At First Major Hurdle

Hit By Lead Drug Failure In OA

 
• By Alexandra Shimmings

Unity is set to drop its lead product based on its senescent cell science as it fails in a Phase II study in osteoarthritis of the knee. Focus switches to ophthalmic product.    

Leaves
Can Unity turn back time? • Source: Shutterstock

UNITY Biotechnology, Inc.’s lead product, UBX0101, has hit the buffers in a Phase II osteoarthritis trial, raising some concern over the viability of its anti-aging thesis.

The 183-patient study found no difference between the p53/MDM2 interaction inhibitor and placebo in patients with moderate-to-severe painful osteoarthritis (OA) of the knee

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.